Europe
Fresh off the heels of its CAR-T approval, Novartis expanded its oncological arsenal with a $3.9B acquisition of Advanced Accelerator Applications.
Late on Friday, Merck announced that it had pulled its application for Keytruda in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous NSCLC from the EMA.
Operating income amounted to €(4,159) K as of June 30, 2017 compared to €(3,711) K as of June 30, 2016.
GE asked branding and creative agency Sub Rosa to help boost its medical device business by making the mammography process more human.
Siemens AG is looking to take its Healthineers unit public.
Drug giant calls for clarity on Brexit and a minimum two-year transition period to avoid disruption to medical supplies.
New antibiotic development seems to go through cycles and many large companies have stayed away from antibiotics or abandoned efforts, despite a growing need for new antibiotics.
Earlier this month, Pfizer’s chairman and CEO, Ian Read, said he was considering selling the company’s Consumer Healthcare business, or possibly spinning it off.
Stryker picked up controlling interest in Vexim, a French medical device company that specializes in the minimally invasive treatment of vertebral fractures.
PRESS RELEASES